Tianhong CNI BIOMEDICINE ETF(159859) Rises 3.41%, Sees Net Inflow of 169 Million Yuan for Five Consecutive Days

NewTimeSpace News, as of 13:51 on May 11, 2026, Tianhong Biopharmaceutical ETF (159859) rose 3.41%, with its latest quoted price at 0.39 yuan. Looking at a longer timeframe, as of May 8, 2026, Tianhong Biopharmaceutical ETF gained 11.08% over the past year, ranking 1/3 among comparable funds in terms of increase. (The stocks listed above are merely index constituents and do not constitute any specific recommendation.)

In terms of liquidity, Tianhong Biopharmaceutical ETF recorded an intraday turnover rate of 5.4%, with a trading volume of 217 million yuan. Over a longer horizon, as of May 8, the ETF's average daily turnover over the past year stood at 119 million yuan, ranking first among comparable funds.

Regarding scale, Tianhong Biopharmaceutical ETF's AUM increased by 134 million yuan over the past two weeks, achieving significant growth, with the new scale increment ranking 1/3 among comparable funds. (Data source: Wind)

In terms of share size, the latest share count of Tianhong Biopharmaceutical ETF reached 10.329 billion units, hitting a one-month high and ranking 1/3 among comparable funds. (Data source: Wind)

From a net capital inflow perspective, Tianhong Biopharmaceutical ETF experienced continuous net inflows for five consecutive days, with the highest single-day net inflow of 73.0442 million yuan, totaling an inflow of 169 million yuan, and an average daily net inflow of 33.8545 million yuan. (Data source: Wind)

Data shows that leveraged funds continue to position themselves. Tianhong Biopharmaceutical ETF saw leveraged fund net purchases for three consecutive days, with the highest single-day net purchase of 9.0806 million yuan, and the latest margin balance stood at 172 million yuan. (Data source: Wind)

As of May 8, Tianhong Biopharmaceutical ETF's net value increased by 10.48% over the past year, ranking first among comparable funds. In terms of return capability, as of May 8, 2026, since its inception, the ETF achieved a highest single-month return of 27.87%, a longest consecutive gaining streak of five months with a cumulative gain of 31.58%, and an average return of 5.35% during up months. As of May 8, 2026, since its inception, the ETF's annualized excess return over its benchmark was 1.92%.

In terms of drawdown, as of May 8, 2026, Tianhong Biopharmaceutical ETF's relative drawdown versus its benchmark since the beginning of the year was 0.08%, the smallest drawdown among comparable funds.

In terms of fees, Tianhong Biopharmaceutical ETF has a management fee rate of 0.50% and a custody fee rate of 0.10%, the lowest fee rates among comparable funds.

In terms of tracking accuracy, as of May 8, 2026, Tianhong Biopharmaceutical ETF's six-month tracking error was 0.015%, the highest tracking precision among comparable funds.

Tianhong Biopharmaceutical ETF closely tracks the CNI Biopharmaceutical Index. The CNI Biopharmaceutical Index takes listed companies related to the biopharmaceutical industry on the Shanghai, Shenzhen, and Beijing stock exchanges as the sample space, and selects the top 30 securities as index constituents based on a comprehensive ranking of market capitalization and liquidity. It reflects the overall operation of the biopharmaceutical industry and provides the market with index-based investment instruments for this sub-sector.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.